ATO is widely reported to be able to degrade and thus inhibit the oncogenic function of mutated p53 [137]; ATO, in fact, suppresses cancer cell growth by targeting mutated p53, for degradation by Pirh2-pathway [138]. Here, TP53 is linked to cancer.